Practically Speaking: Targeted Therapy for EGFR EXON 20 Ins Mutated NSCLC

To be added to the distribution list, please email: DDeCastro@southlakeregional.org

In this episode, Dr. Natasha Leighl will discuss the incorporation of Amivantamab into the treatment landscape for EGFR EXON 20 insertion mutated NSCLC, also focusing on toxicity management.

Key Opinion Leader: 
Dr. Natasha Leighl MD. MMSc, FRCPC, FASCO
Lung Site Lead, Medical Oncology
Princess Margaret Cancer Centre
OSI Pharmaceuticals Foundation Chair, PMC Foundation
Professor, Department of Medicine, University of Toronto
Adjunct Professor, IHPME, Dalla Lana School of Public Health

Host:
Dr. Shaqil Kassam MD. MSc. FRCPC
skassam@southlakeregional.org
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

Outline:
0:00 - Introduction
1:30  – Dr. Natasha Leighl 
3:00  – First line treatment options EGFR Exon 20ins
4:00 – Different EGFR Exon 20ins and treatment choice.
7:30 – Sequencing Mobocertinb vs. Amivantimab 2nd or 3rd line? 
10:30 – Role for 1st line Chemo IO in EGFR Exon 20ins? 
12:00 – Mobocertinb vs. Amivantimab 
14:40 – Infusion reactions and Chair time considerations 
19:30 – Squamous NSCLC
22:00 – Toxicity Management. 

Previous episodes: https://www.blogtalkradio.com/medoncnow